The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

Read about vaccine sales, Akums and more in the latest Market Talks covering Health Care.

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased ...

The new prefilled syringe has the same composition but removes the need for reconstitution, providing a more convenient option for health care providers who administer vaccines. According to the ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...